CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
13.03
+0.28 (2.20%)
At close: Sep 9, 2025, 4:00 PM
13.20
+0.17 (1.30%)
After-hours: Sep 9, 2025, 7:59 PM EDT
CorMedix Revenue
CorMedix had revenue of $39.74M in the quarter ending June 30, 2025, with 4,829.40% growth. This brings the company's revenue in the last twelve months to $121.48M, up 14,970.29% year-over-year. In the year 2024, CorMedix had annual revenue of $43.47M.
Revenue (ttm)
$121.48M
Revenue Growth
+14,970.29%
P/S Ratio
6.80
Revenue / Employee
$1,868,992
Employees
65
Market Cap
972.68M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.47M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CRMD News
- 1 day ago - CorMedix Announces Strategic Minority Investment in Talphera - GlobeNewsWire
- 1 day ago - Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market - PRNewsWire
- 7 days ago - CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team - GlobeNewsWire
- 12 days ago - CorMedix to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - CorMedix: The Undervalued Breakthrough - Seeking Alpha
- 4 weeks ago - CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - CorMedix to Buy Melinta Therapeutics for $300 Million - WSJ
- 4 weeks ago - Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership - Business Wire